Patents by Inventor Gary Swergold

Gary Swergold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
    Patent number: 11116839
    Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: September 14, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: Gary Swergold
  • Methods for Treating Autosomal Dominant Hypercholesterolemia Associated with PCSK9 Gain-Of-Function Mutations
    Publication number: 20190330371
    Abstract: The present invention provides methods for treating autosomal dominant hypercholesterolemia (ADH). According to certain embodiments, the ADH is caused by or associated with a gain-of-function mutation (GOFm) in a gene encoding PCSK9. The present invention therefore includes methods comprising selecting a patient who carries a GOFm in one or both alleles of the PCSK9 gene, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Application
    Filed: March 28, 2019
    Publication date: October 31, 2019
    Inventors: Gary SWERGOLD, Scott MELLIS, William J. SASIELA
  • METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
    Publication number: 20180333490
    Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Application
    Filed: August 2, 2018
    Publication date: November 22, 2018
    Inventor: Gary Swergold
  • Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
    Patent number: 10111953
    Abstract: The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: October 30, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Gary Swergold, William J. Sasiela, Robert C. Pordy
  • Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
    Patent number: 10076571
    Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: September 18, 2018
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Gary Swergold
  • Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9
    Publication number: 20170296657
    Abstract: The present invention provides methods for treating hypercholesterolemia and reducing LDL-C. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: June 22, 2017
    Publication date: October 19, 2017
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald, Gary Swergold, Robert C. Pordy, William J. Sasiela
  • Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
    Patent number: 9724411
    Abstract: The present invention provides methods for treating hypercholesterolemia and reducing LDL-C. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: August 8, 2017
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald, Gary Swergold, Robert C. Pordy, William J. Sasiela
  • METHODS FOR TREATING AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA ASSOCIATED WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
    Publication number: 20140356370
    Abstract: The present invention provides methods for treating autosomal dominant hypercholesterolemia (ADH). According to certain embodiments, the ADH is caused by or associated with a gain-of-function mutation (GOFm) in a gene encoding PCSK9. The present invention therefore includes methods comprising selecting a patient who carries a GOFm in one or both alleles of the PCSK9 gene, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Application
    Filed: May 29, 2014
    Publication date: December 4, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gary SWERGOLD, Scott MELLIS, William J. SASIELA
  • METHODS FOR REDUCING REMNANT CHOLESTEROL AND OTHER LIPOPROTEIN FRACTIONS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
    Publication number: 20140356371
    Abstract: The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits elevated serum lipoproteins, and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Application
    Filed: May 29, 2014
    Publication date: December 4, 2014
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: Gary SWERGOLD, William J. SASIELA, Robert C. PORDY
  • Methods for Treating Hypercholesterolemia and Reducing LDL-C Using Antibodies to PCSK9
    Publication number: 20140099312
    Abstract: The present invention provides methods for treating hypercholesterolemia and reducing LDL-C. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: December 9, 2013
    Publication date: April 10, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald, Gary Swergold, Robert C. Pordy, William J. Sasiela
  • METHODS FOR REDUCING LIPOPROTEIN(a) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
    Publication number: 20130243784
    Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.
    Type: Application
    Filed: September 12, 2012
    Publication date: September 19, 2013
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventor: Gary Swergold
  • Methods for treating hypercholesterolemia using antibodies to PCSK9
    Patent number: 8357371
    Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: January 22, 2013
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Mark W. Sleeman, Joel H. Martin, Tammy T. Huang, Douglas MacDonald, Gary Swergold
  • Methods for Treating Hypercholesterolemia Using Antibodies to PCSK9
    Publication number: 20110256148
    Abstract: The present invention provides methods for treating hypercholesterolemia. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.
    Type: Application
    Filed: April 27, 2011
    Publication date: October 20, 2011
    Applicant: REGENERON PHARMACEUTICALS, INC.
    Inventors: MARK W. SLEEMAN, JOEL H. MARTIN, TAMMY T. HUANG, DOUGLAS MACDONALD, GARY SWERGOLD